NCT06863129 (PERFORM) is a NA clinical trial of Internal Fixation in Metastatic Bone Disease, sponsored by Michelle Ghert, MD.

Who is sponsoring NCT06863129?

NCT06863129 is sponsored by Michelle Ghert, MD.

What drugs are being tested in NCT06863129?

Interventions in NCT06863129: Internal Fixation, Resection and reconstruction.

What condition does NCT06863129 study?

NCT06863129 studies Metastatic Bone Disease.

Is NCT06863129 still recruiting?

NCT06863129 is currently recruiting now. Last updated 10 November 2025.

Last reviewed 2025-11-10 · How we verify

NCT06863129: PERFORM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proximal FEmur Reconstruction or Internal Fixation fOR Metastases (PERFORM) Trial

Recruiting now NA Last updated 10 November 2025

What this trial tests

NA trial testing Internal Fixation in Metastatic Bone Disease in 334 participants. Currently enrolling.

Timeline

1 February 2025

Primary endpoint
1 June 2029

1 June 2030

Quick facts

Lead sponsor	Michelle Ghert, MD
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	334
Start date	1 February 2025
Primary completion	1 June 2029
Estimated completion	1 June 2030
Sites	6 locations across Belgium, Italy, United States, Brazil

Drugs / interventions tested

Internal Fixation
Resection and reconstruction

Conditions studied

Metastatic Bone Disease — all drugs for Metastatic Bone Disease →

Sponsor

Michelle Ghert, MD

Who can join

18 and older, any sex, with Metastatic Bone Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to find out if removing and replacing part of the hip bone works better than using metal hardware to stabilize the bone in patients whose cancer has spread to the hip. The main questions are: 1. Does removing and replacing part of the bone work better than just stabilizing it with metal hardware? 2. Does removing and replacing the bone help reduce problems like cancer coming back or the metal hardware breaking? Researchers will compare two treatments: using metal rods and plates to stabilize the bone (internal fixation) versus removing part of the bone and possibly replacing the hip joint (resection and reconstruction) to see if the second option causes fewer problems. Participants will: * Be randomly assigned to one of two groups (internal fixation or resection and reconstruction). * Have one of the two surgeries based on which group they're in. * Go to follow-up appointments with the study doctor at 2 weeks, 6 weeks, 4 months, 6 months, 9 months, and 12 months after surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Internal Fixation

Trials testing the same drug.

NCT03966716 — Hips Screws or (Total) Hip Replacement for Undisplaced Femoral Neck Fractures in Elderly Patients (HipSTHeR) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06863129 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michelle Ghert, MD
Last refreshed: 10 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06863129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing